Mouse Model for Human Vitiligo

Overview

Journal Curr Protoc Immunol

Specialty Allergy & Immunology

Date 2018 Sep 26

PMID 30253067

Citations 16

Authors

Rebecca L Riding

Jillian M Richmond

John E Harris

Affiliations

Soon will be listed here.

Abstract

Vitiligo is an autoimmune skin disease in which the pigment-producing melanocytes are destroyed by autoreactive CD8 T cells. As a result, patients develop disfiguring white spots on the skin. This article discusses the first mouse model of vitiligo that develops epidermal depigmentation, similar to disease in human patients. To achieve epidermal depigmentation, mice are genetically engineered to retain melanocytes in the skin epidermis. Induction of disease occurs by adoptive transfer of melanocyte-specific CD8 T cells into recipient mice and the subsequent activation of these T cells using a viral vector. Depigmentation of the epidermis occurs within 5 to 7 weeks in a patchy pattern similar to patients with vitiligo. This article describes the methods of vitiligo induction, quantification of lesion progression and regression, processing of the skin for detailed analysis, and how to use this model to inform clinical studies. © 2018 by John Wiley & Sons, Inc.

Citing Articles

Sirtuin1 Deficiency Could Exacerbate Melanocyte Apoptosis Under Endoplasmic Reticulum Stress.

Zhu J, Guo Y, Luo L, Huang X, Wei T, Zuo B Inflammation. 2025; .

PMID: 39921788 DOI: 10.1007/s10753-025-02255-y.

Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity.

Ezzedine K, Tannous R, Pearson T, Harris J J Clin Invest. 2025; 135(2.

PMID: 39817457 PMC: 11735104. DOI: 10.1172/JCI185785.

3D-hUMSCs Exosomes Ameliorate Vitiligo by Simultaneously Potentiating Treg Cells-Mediated Immunosuppression and Suppressing Oxidative Stress-Induced Melanocyte Damage.

Wang Q, Guo W, Niu L, Zhou Y, Wang Z, Chen J Adv Sci (Weinh). 2024; 11(31):e2404064.

PMID: 38887870 PMC: 11336971. DOI: 10.1002/advs.202404064.

Sexual dimorphism in melanocyte stem cell behavior reveals combinational therapeutic strategies for cutaneous repigmentation.

An L, Kim D, Donahue L, Mejooli M, Eom C, Nishimura N Nat Commun. 2024; 15(1):796.

PMID: 38280858 PMC: 10821900. DOI: 10.1038/s41467-024-45034-3.

Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin.

Tang Q, Fakih H, Zain Ui Abideen M, Hildebrand S, Afshari K, Gross K Nat Commun. 2023; 14(1):7099.

PMID: 37925520 PMC: 10625637. DOI: 10.1038/s41467-023-42714-4.

References

Alikhan A, Felsten L, Daly M, Petronic-Rosic V . Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011; 65(3):473-491. DOI: 10.1016/j.jaad.2010.11.061. View

Richmond J, Strassner J, Zapata Jr L, Garg M, Riding R, Refat M . Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018; 10(450). PMC: 6495055. DOI: 10.1126/scitranslmed.aam7710. View

Spritz R . Modern vitiligo genetics sheds new light on an ancient disease. J Dermatol. 2013; 40(5):310-8. PMC: 3783942. DOI: 10.1111/1346-8138.12147. View

Thornton A . Fractionation of T and B cells using magnetic beads. Curr Protoc Immunol. 2008; Chapter 3:Unit 3.5A. DOI: 10.1002/0471142735.im0305as57. View

Falabella R . Vitiligo and the melanocyte reservoir. Indian J Dermatol. 2010; 54(4):313-8. PMC: 2807704. DOI: 10.4103/0019-5154.57604. View

Strassner J, Rashighi M, Refat M, Richmond J, Harris J . Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017; 76(5):847-855.e5. PMC: 5392432. DOI: 10.1016/j.jaad.2016.12.021. View

Richmond J, Masterjohn E, Chu R, Tedstone J, Youd M, Harris J . CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice. J Invest Dermatol. 2017; 137(4):982-985. DOI: 10.1016/j.jid.2016.10.048. View

Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim H, Hamzavi I . Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol. 2015; 74(2):295-302. DOI: 10.1016/j.jaad.2015.08.063. View

van den Boorn J, Konijnenberg D, Dellemijn T, van der Veen J, Bos J, Melief C . Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009; 129(9):2220-32. DOI: 10.1038/jid.2009.32. View

10.

Harris J . Optimizing Vitiligo Management: Past, Present, and Future. Dermatol Clin. 2017; 35(2):xi. DOI: 10.1016/j.det.2017.01.001. View

11.

Autengruber A, Gereke M, Hansen G, Hennig C, Bruder D . Impact of enzymatic tissue disintegration on the level of surface molecule expression and immune cell function. Eur J Microbiol Immunol (Bp). 2014; 2(2):112-20. PMC: 3956959. DOI: 10.1556/EuJMI.2.2012.2.3. View

12.

van den Boorn J, Melief C, Luiten R . Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res. 2011; 24(4):673-9. DOI: 10.1111/j.1755-148X.2011.00878.x. View

13.

Frisoli M, Harris J . Vitiligo: Mechanistic insights lead to novel treatments. J Allergy Clin Immunol. 2017; 140(3):654-662. DOI: 10.1016/j.jaci.2017.07.011. View

14.

Holmes K, Lantz L, Fowlkes B, Schmid I, Giorgi J . Preparation of cells and reagents for flow cytometry. Curr Protoc Immunol. 2008; Chapter 5:Unit 5.3. DOI: 10.1002/0471142735.im0503s44. View

15.

Reeves J, Reeves P . Removal of lymphoid organs. Curr Protoc Immunol. 2008; Chapter 1:Unit 1.9. DOI: 10.1002/0471142735.im0109s01. View

16.

Rodrigues M, Ezzedine K, Hamzavi I, Pandya A, Harris J . Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017; 77(1):17-29. DOI: 10.1016/j.jaad.2016.11.010. View

17.

Nishimura E, Yoshida H, Kunisada T, Nishikawa S . Regulation of E- and P-cadherin expression correlated with melanocyte migration and diversification. Dev Biol. 1999; 215(2):155-66. DOI: 10.1006/dbio.1999.9478. View

18.

Donovan J, Brown P . Animal identification. Curr Protoc Immunol. 2008; Chapter 1:1.5.1-1.5.4. DOI: 10.1002/0471142735.im0105s73. View

19.

Majumdar M, Feng L, Medlock E, Toksoz D, Williams D . Identification and mutation of primary and secondary proteolytic cleavage sites in murine stem cell factor cDNA yields biologically active, cell-associated protein. J Biol Chem. 1994; 269(2):1237-42. View

20.

Harris J . Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev. 2015; 269(1):11-25. PMC: 4685729. DOI: 10.1111/imr.12369. View